Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: Implications for interpreting the women's health study

Journal of Thrombosis and Thrombolysis

Volumn 28, Issue 1, 2009, Pages 94-100

  Swaim, Lisa ^a   Hillman, Robert S ^a  

^a Accumetrics Inc   (United States)

Author keywords

Aspirin; Aspirinnon responsiveness; Dosing; Point of care assay

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID;

ADULT; ARTICLE; BLOOD CLOTTING TEST; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FUNCTION TEST; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OUTCOME ASSESSMENT; POINT OF CARE TESTING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; TREATMENT DURATION; TREATMENT RESPONSE; WOMEN'S HEALTH;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; PLATELET ACTIVATION; TIME FACTORS; WOMEN'S HEALTH;

EID: 67449087713     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-008-0262-6     Document Type: Article

References (24)

1. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86. doi: 10.1136/bmj.324.7336.S71
2. Ridker PM, Cook NR, Lee I et al (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352:1293-1304. doi: 10.1056/NEJMoa050613
3. Patrignani P, Filabozzi P, Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69:1366-1372. doi: 10.1172/JCI110576
4. VerifyNow® Aspirin package insert
5. Karha J, Rajagopal V, Kottke-Marchant K, Bhatt DL (2006) Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J 151:976.e7-976.e11
6. Eikelboom JW, Hirsh J, Weitz JI et al (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650-1655. doi: 10.1161/ 01.CIR.0000013777.21160.07
7. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol E (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961-965. doi: 10.1016/S0735-1097(02)03014-0
8. Cheng X, Chen WH, Lee PY et al (2005) Prevalence, profile, predictors, and natural history of aspirin resistance measured by the Ultegra Rapid Platelet Function Assay-ASA in patients with coronary heart disease. Poster presented at the American Heart Association 6th scientific forum on quality of care and outcomes research in cardiovascular disease and stroke, P145, Washington, DC, May 2005
9. Chen WH, Lee PY, Ng W et al (2004) Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43:1122-1126. doi: 10.1016/j.jacc.2003.12.034
10. Chen WH, Lee PY, Ng W et al (2005) Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol 96:760-763. doi: 10.1016/ j.amjcard.2005.04.056
11. Peters RJG, Mehta SR, Fox KAA et al (2003) Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events study. Circulation 108:1682-1687. doi: 10.1161/01.CIR.0000091201.39590.CB
12. FitzGerald GA, Oates JA, Hawiger J et al (1983) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71:676-688. doi: 10.1172/ JCI110814
13. Perneby C, Hakan Wallen N, Rooney C, Fitzgerald D, Hjemdahl P (2006) Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 95:652-658
14. Ridker PM, Hennekens CH, Tofler GH, Lipinska I, Buring JE (1996) Anti-platelet effects of 100 mg alternate day oral aspirin: A randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women. J Cardiovasc Risk 3:209-212. doi: 10.1097/00043798-199604000-00013
15. Becker DM, Segal J, Vaidya D et al (2006) Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 295:1420-1427. doi: 10.1001/jama.295.12.1420
16. Wang JC, Aucoin-Barry D, Manuelian D et al (2003) Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 92:1492-1494. doi: 10.1016/j.amjcard.2003.08.072
17. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB (2006) Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 97:567-570. doi: 10.1016/j.amjcard.2005.09.093
18. Cavallari LH, Helgason CM, Brace LD, Viana MAG, Nutescu EA (2006) Sex difference in the antiplatelet effect of aspirin in patients with stroke. Ann Pharmacother 40(5):812-817
19. Bruno A et al (2004) Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. Stroke 35(3):727-730. doi: 10.1161/01.STR.0000117097.76953.A6
20. Alberts MJ et al (2004) Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 35(1):175-178. doi: 10.1161/ 01.STR.0000106763.46123.F6
21. Cerletti C et al (2003) Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 42(12):1059-1070. doi: 10.2165/00003088-200342120-00004
22. Hart RG et al (2003) Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy 23(5):579-584. doi: 10.1592/phco.23.5.579.32206
23. Coleman JL, Wang JC, Simon DI (2004) Determination of individual response to aspirin therapy using the Accumetrics Ultegra RPFA-ASA system. Point Care 3:77-82
24. Lee PY, Chen WH, Ng W et al (2005) Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 118:723-727. doi: 10.1016/j.amjmed.2005.03.041